Skip to main content

Press release: novel prognostic marker for CV risk in T2D

A novel prognostic marker for cardiovascular risk in individuals with type 2 diabetes (T2D) has been identified by the IMMEDIAB team – Immunity and Metabolism of Diabetes, led by Nicolas Venteclef at INEM - Institut Necker Enfants Malades.

This breakthrough, the result of collective and collaborative efforts, positions our researchers at the forefront of a significant scientific leap. The study, involving phenotypic, transcriptomic, and metabolomic analyses across three cohorts of T2D patients - AngioSafe-2, GLUTADIAB, and SURDIAGENE - reveals a correlation between the number of circulating monocytes and an increased risk of cardiovascular events such as stroke or myocardial infarction over a decade.

Published in Circulation Research and highlighted in an INSERM press release, this work is a substantial step forward in understanding, assessing, and preventing cardiovascular incidents in type 2 diabetic patients. With a patent already filed for this discovery and the ongoing development of a cutting-edge electronic sensor for measuring circulating monocytes from a single drop of blood, this innovation promises to transform patient care.

The potential impact of this research on the cardiovascular health of millions of people with type 2 diabetes is immense, ushering in new and promising horizons in the medical field.
Stay tuned for what's next!

To read the press release, visit:

To learn more about the study: 

Photo credit: Magazine Science & Santé, Jan-Feb 2013, rubrique Grand angle, p30